Another great video by LL explaining how DCVax-L works, and how it works even more effectively with the CIs and the TLRs like Poly-ICLC.
At a little bit after the 13:50 minute mark, she describes how when the DCs pick up antigens from the dead tumor cells that might be newer (neoantigens?), and we’re not found on the original tumor from which the lysate was made, they could induce a “perpetuated immune response.”
So around the 30 minute point, LL describes in more considerable more detail how the TLRs (Poly ICLC) work with DCVax, thus explaining why the results might be significantly improved by adding this “stimulator” to the immune stimulators.
At the 37 minute mark, she describes an increased “interferon (gama) signature” in the peripheral blood as a potential bio marker to a longer term survival.
Around the 40 minute mark, she talks about a new trial they have planned (based on preclinical mice trials) to go after the immunosuppressive macrophages and myeloid cells that often are battling the T cells by adding a CSF1 inhibitor that is intended to block these immunosuppressive cells.
At about the 51 minute mark, she explains in some detail why the dendritic cell is such a great gatekeeper (or rather communicator) to the immune system alerting it as to what it needs to recognize as a problem.
At around the 57 minut mark, she indicates that the reason why the older patients did so well on DCVax is because their tumors are more mutated and are the made up of the more mesenchymal subtype. So even though a younger patient may have a more robust immune system, their tumors tend to be less mutated. She thinks because the older patients don’t have as strong an immune system, their tumors are more mutated (typically, that’s a much worse scenario); however, those are the types of tumors that immunotherapies do best with.
Anyhow, lots of good stuff in this latest LL video! Thank you! :)